$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 10 2021 | REGN | REGENERON PHARMACE ... | McCourt Marion | EVP Commercial | Option Exercise | M | 342.93 | 1,000 | 342,930 | 17,000 | |
May 10 2021 | REGN | REGENERON PHARMACE ... | McCourt Marion | EVP Commercial | Sell | S | 495.63 | 1,000 | 495,630 | 17,038 | 18 K to 17 K (-5.54 %) |
May 10 2021 | REGN | REGENERON PHARMACE ... | McCourt Marion | EVP Commercial | Buy | M | 342.93 | 1,000 | 342,930 | 18,038 | 17 K to 18 K (+5.87 %) |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Option Exercise | M | 52.03 | 248,079 | 12,907,550 | 0 | |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Option Exercise | M | 52.03 | 1,921 | 99,950 | 0 | |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 414 | 0 | 142,796 | 143.2 K to 142.8 K (-0.29 %) |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Payment of Exercise | F | 458.48 | 137,998 | 63,269,323 | 349,090 | 487.1 K to 349.1 K (-28.33 %) |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Buy | M | 52.03 | 248,079 | 12,907,550 | 487,088 | 239 K to 487.1 K (+103.79 %) |
Feb 24 2021 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Buy | M | 52.03 | 1,921 | 99,950 | 239,009 | 237.1 K to 239 K (+0.81 %) |
Feb 18 2021 | REGN | REGENERON PHARMACE ... | REGENERON PHARMACEUTICALS, INC ... | 10% Owner | Option Exercise | C | 0.00 | 14,000,000 | 0 | 0 | |
Feb 18 2021 | REGN | REGENERON PHARMACE ... | REGENERON PHARMACEUTICALS, INC ... | 10% Owner | Option Exercise | C | 0.00 | 12,500,000 | 0 | 0 | |
Feb 18 2021 | REGN | REGENERON PHARMACE ... | REGENERON PHARMACEUTICALS, INC ... | 10% Owner | Buy | C | 0.00 | 2,097,314 | 0 | 2,097,314 | 0 to 2.1 M |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 512.82 | 2 | 1,026 | 23,691 | 23.7 K to 23.7 K (-0.01 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 509.28 | 4 | 2,037 | 23,693 | 23.7 K to 23.7 K (-0.02 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 508.52 | 16 | 8,136 | 23,697 | 23.7 K to 23.7 K (-0.07 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 507.39 | 22 | 11,163 | 23,713 | 23.7 K to 23.7 K (-0.09 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 506.44 | 30 | 15,193 | 23,735 | 23.8 K to 23.7 K (-0.13 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 505.60 | 17 | 8,595 | 23,765 | 23.8 K to 23.8 K (-0.07 %) |
Feb 02 2021 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 504.68 | 9 | 4,542 | 23,782 | 23.8 K to 23.8 K (-0.04 %) |
Jan 27 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 380.95 | 2,480 | 944,756 | 2,479 | |
Jan 27 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 554.32 | 2,480 | 1,374,714 | 891 | 3.4 K to 891 (-73.57 %) |
Jan 27 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 380.95 | 2,480 | 944,756 | 3,371 | 891 to 3.4 K (+278.34 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Grant | A | 0.00 | 248 | 0 | 891 | 643 to 891 (+38.57 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Grant | A | 0.00 | 248 | 0 | 891 | 643 to 891 (+38.57 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Grant | A | 0.00 | 248 | 0 | 54,663 | 54.4 K to 54.7 K (+0.46 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Grant | A | 0.00 | 248 | 0 | 54,663 | 54.4 K to 54.7 K (+0.46 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Grant | A | 0.00 | 248 | 0 | 891 | 643 to 891 (+38.57 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 248 | 0 | 2,078 | 1.8 K to 2.1 K (+13.55 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Option Exercise | A | 0.00 | 620,270 | 0 | 620,270 | |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Option Exercise | M | 52.03 | 158,079 | 8,224,850 | 0 | |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Option Exercise | M | 52.03 | 240,000 | 12,487,200 | 158,079 | |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Gift | G | 0.00 | 57,465 | 0 | 0 | 57.5 K to 0 (-100.00 %) |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Payment of Exercise | F | 483.25 | 86,096 | 41,605,892 | 822,207 | 908.3 K to 822.2 K (-9.48 %) |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Buy | M | 52.03 | 158,079 | 8,224,850 | 908,303 | 750.2 K to 908.3 K (+21.07 %) |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Payment of Exercise | F | 483.25 | 130,714 | 63,167,541 | 750,224 | 880.9 K to 750.2 K (-14.84 %) |
Dec 31 2020 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and Chief ... | Buy | M | 52.03 | 240,000 | 12,487,200 | 880,938 | 640.9 K to 880.9 K (+37.45 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Option Exercise | A | 492.00 | 25,000 | 12,300,000 | 25,000 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 1,929 | 0 | 57,350 | 55.4 K to 57.4 K (+3.48 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 8,285 | 0 | 55,421 | 47.1 K to 55.4 K (+17.58 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Option Exercise | A | 492.00 | 27,680 | 13,618,560 | 27,680 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 2,406 | 0 | 3,609 | 1.2 K to 3.6 K (+200.00 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 2,406 | 0 | 47,786 | 50.2 K to 47.8 K (-4.79 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 349 | 0 | 143,210 | 143.6 K to 143.2 K (-0.24 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Grant | A | 0.00 | 2,439 | 0 | 237,088 | 234.6 K to 237.1 K (+1.04 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Grant | A | 0.00 | 5,000 | 0 | 26,931 | 21.9 K to 26.9 K (+22.80 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Grant | A | 0.00 | 1,930 | 0 | 21,931 | 20 K to 21.9 K (+9.65 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | A | 492.00 | 25,000 | 12,300,000 | 25,000 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 2,000 | 0 | 17,038 | 15 K to 17 K (+13.30 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 1,075 | 0 | 15,038 | 14 K to 15 K (+7.70 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | A | 492.00 | 17,500 | 8,610,000 | 17,500 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Grant | A | 0.00 | 1,688 | 0 | 24,715 | 23 K to 24.7 K (+7.33 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Gift | G | 0.00 | 750 | 0 | 20,979 | 21.7 K to 21 K (-3.45 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | A | 492.00 | 10,000 | 4,920,000 | 10,000 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 25 | 0 | 25 | 0 to 25 |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 25 | 0 | 25 | 0 to 25 |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 50 | 0 | 0 | 50 to 0 (-100.00 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 1,750 | 0 | 21,102 | 19.4 K to 21.1 K (+9.04 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 969 | 0 | 19,352 | 18.4 K to 19.4 K (+5.27 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Grant | A | 0.00 | 1,930 | 0 | 25,903 | 24 K to 25.9 K (+8.05 %) |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Grant | A | 0.00 | 1,930 | 0 | 16,368 | 14.4 K to 16.4 K (+13.37 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 524.31 | 3 | 1,573 | 23,643 | 23.6 K to 23.6 K (-0.01 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 523.32 | 10 | 5,233 | 23,646 | 23.7 K to 23.6 K (-0.04 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 522.45 | 14 | 7,314 | 23,656 | 23.7 K to 23.7 K (-0.06 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 521.50 | 10 | 5,215 | 23,670 | 23.7 K to 23.7 K (-0.04 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 520.58 | 27 | 14,056 | 23,680 | 23.7 K to 23.7 K (-0.11 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 519.60 | 13 | 6,755 | 23,707 | 23.7 K to 23.7 K (-0.05 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 518.55 | 6 | 3,111 | 23,720 | 23.7 K to 23.7 K (-0.03 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 517.63 | 11 | 5,694 | 23,726 | 23.7 K to 23.7 K (-0.05 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 516.37 | 4 | 2,065 | 23,737 | 23.7 K to 23.7 K (-0.02 %) |
Dec 02 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 515.64 | 2 | 1,031 | 23,741 | 23.7 K to 23.7 K (-0.01 %) |
Nov 13 2020 | REGN | REGENERON PHARMACE ... | COLES N ANTHONY | Director | Option Exercise | M | 345.47 | 11 | 3,800 | 13,039 | |
Nov 13 2020 | REGN | REGENERON PHARMACE ... | COLES N ANTHONY | Director | Buy | M | 345.47 | 11 | 3,800 | 654 | 643 to 654 (+1.71 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 556.02 | 10 | 5,560 | 23,743 | 23.8 K to 23.7 K (-0.04 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 552.39 | 20 | 11,048 | 23,753 | 23.8 K to 23.8 K (-0.08 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 548.58 | 20 | 10,972 | 23,773 | 23.8 K to 23.8 K (-0.08 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 546.40 | 20 | 10,928 | 23,793 | 23.8 K to 23.8 K (-0.08 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 545.59 | 10 | 5,456 | 23,813 | 23.8 K to 23.8 K (-0.04 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 544.54 | 20 | 10,891 | 23,823 | 23.8 K to 23.8 K (-0.08 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Gift | G | 0.00 | 2,000 | 0 | 24,343 | 26.3 K to 24.3 K (-7.59 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Gift | G | 0.00 | 1,000 | 0 | 26,323 | 27.3 K to 26.3 K (-3.66 %) |
Nov 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Gift | G | 0.00 | 1,500 | 0 | 27,323 | 28.8 K to 27.3 K (-5.20 %) |
Oct 23 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Option Exercise | M | 52.03 | 1,921 | 99,950 | 0 | |
Oct 23 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Option Exercise | M | 30.63 | 3,264 | 99,976 | 0 | |
Oct 23 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Buy | M | 30.63 | 3,264 | 99,976 | 47,136 | 43.9 K to 47.1 K (+7.44 %) |
Oct 23 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Buy | M | 52.03 | 1,921 | 99,950 | 43,872 | 42 K to 43.9 K (+4.58 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 520.01 | 9,212 | 4,790,332 | 0 | |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 600.00 | 9,212 | 5,527,200 | 5,643 | 14.9 K to 5.6 K (-62.01 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 520.01 | 9,212 | 4,790,332 | 14,855 | 5.6 K to 14.9 K (+163.25 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | M | 342.93 | 1,000 | 342,930 | 18,000 | |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | M | 342.93 | 1,000 | 342,930 | 19,000 | |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Sell | S | 600.00 | 1,000 | 600,000 | 13,963 | 15 K to 14 K (-6.68 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Buy | M | 342.93 | 1,000 | 342,930 | 14,963 | 14 K to 15 K (+7.16 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Sell | S | 612.15 | 1,000 | 612,150 | 13,963 | 15 K to 14 K (-6.68 %) |
Oct 06 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Buy | M | 342.93 | 1,000 | 342,930 | 14,963 | 14 K to 15 K (+7.16 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 380.95 | 2,480 | 944,756 | 4,959 | |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 376.69 | 2,610 | 983,161 | 0 | |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 552.36 | 1,000 | 552,360 | 9,349 | 10.3 K to 9.3 K (-9.66 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Gift | G | 0.00 | 1,000 | 0 | 10,349 | 11.3 K to 10.3 K (-8.81 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 552.36 | 5,090 | 2,811,512 | 643 | 5.7 K to 643 (-88.78 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 376.69 | 2,610 | 983,161 | 5,733 | 3.1 K to 5.7 K (+83.57 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 380.95 | 2,480 | 944,756 | 3,123 | 643 to 3.1 K (+385.69 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 380.95 | 4,960 | 1,889,512 | 2,479 | |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 376.69 | 7,830 | 2,949,483 | 0 | |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 371.40 | 3,784 | 1,405,378 | 0 | |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 552.36 | 20 | 11,047 | 5,643 | 5.7 K to 5.6 K (-0.35 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 555.74 | 1,530 | 850,282 | 5,663 | 7.2 K to 5.7 K (-21.27 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 554.82 | 899 | 498,783 | 7,193 | 8.1 K to 7.2 K (-11.11 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 553.17 | 1,101 | 609,040 | 8,092 | 9.2 K to 8.1 K (-11.98 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 552.01 | 513 | 283,181 | 9,193 | 9.7 K to 9.2 K (-5.29 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 551.09 | 1,501 | 827,186 | 9,706 | 11.2 K to 9.7 K (-13.39 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 550.11 | 1,600 | 880,176 | 11,207 | 12.8 K to 11.2 K (-12.49 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 549.07 | 2,600 | 1,427,582 | 12,807 | 15.4 K to 12.8 K (-16.88 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 548.13 | 3,654 | 2,002,867 | 15,407 | 19.1 K to 15.4 K (-19.17 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 547.28 | 1,356 | 742,112 | 19,061 | 20.4 K to 19.1 K (-6.64 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 546.01 | 800 | 436,808 | 20,417 | 21.2 K to 20.4 K (-3.77 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 544.96 | 700 | 381,472 | 21,217 | 21.9 K to 21.2 K (-3.19 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 543.19 | 300 | 162,957 | 21,917 | 22.2 K to 21.9 K (-1.35 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 376.69 | 7,830 | 2,949,483 | 22,217 | 14.4 K to 22.2 K (+54.42 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 380.95 | 4,960 | 1,889,512 | 14,387 | 9.4 K to 14.4 K (+52.61 %) |
Sep 23 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 371.40 | 3,784 | 1,405,378 | 9,427 | 5.6 K to 9.4 K (+67.06 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 591.50 | 18 | 10,647 | 28,443 | 28.5 K to 28.4 K (-0.06 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 600.30 | 2 | 1,201 | 28,461 | 28.5 K to 28.5 K (-0.01 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 601.13 | 20 | 12,023 | 28,463 | 28.5 K to 28.5 K (-0.07 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 602.33 | 10 | 6,023 | 28,483 | 28.5 K to 28.5 K (-0.04 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 605.62 | 10 | 6,056 | 28,493 | 28.5 K to 28.5 K (-0.04 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 608.69 | 20 | 12,174 | 28,503 | 28.5 K to 28.5 K (-0.07 %) |
Sep 03 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 616.74 | 20 | 12,335 | 28,523 | 28.5 K to 28.5 K (-0.07 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 52.03 | 4,000 | 208,120 | 0 | |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 52.03 | 6,000 | 312,180 | 4,000 | |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 615.04 | 4,672 | 2,873,467 | 14,438 | 19.1 K to 14.4 K (-24.45 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 614.87 | 2,131 | 1,310,288 | 19,110 | 21.2 K to 19.1 K (-10.03 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 52.03 | 4,000 | 208,120 | 21,241 | 17.2 K to 21.2 K (+23.20 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 614.87 | 3,197 | 1,965,739 | 17,241 | 20.4 K to 17.2 K (-15.64 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 52.03 | 6,000 | 312,180 | 20,438 | 14.4 K to 20.4 K (+41.56 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 614.51 | 1,900 | 1,167,569 | 54,415 | 56.3 K to 54.4 K (-3.37 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 613.54 | 1,100 | 674,894 | 56,315 | 57.4 K to 56.3 K (-1.92 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 612.27 | 2,000 | 1,224,540 | 57,415 | 59.4 K to 57.4 K (-3.37 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 611.38 | 1,400 | 855,932 | 59,415 | 60.8 K to 59.4 K (-2.30 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 610.45 | 3,600 | 2,197,620 | 60,815 | 64.4 K to 60.8 K (-5.59 %) |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Option Exercise | M | 33.42 | 15,000 | 501,300 | 0 | |
Aug 31 2020 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Option Exercise | M | 25.45 | 25,000 | 636,250 | 0 |